Search Results - "TRABOULSEE, A"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    What Have We Learned from Perfusion MRI in Multiple Sclerosis? by Lapointe, E, Li, D K B, Traboulsee, A L, Rauscher, A

    Published in American journal of neuroradiology : AJNR (01-06-2018)
    “…Using MR imaging, perfusion can be assessed either by dynamic susceptibility contrast MR imaging or arterial spin-labeling. Alterations of cerebral perfusion…”
    Get full text
    Journal Article
  5. 5

    Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology by Laule, C, Leung, E, Li, D KB, Traboulsee, A L, Paty, D W, MacKay, A L, Moore, G RW

    Published in Multiple sclerosis (01-12-2006)
    “…Various magnetic resonance (MR) techniques are used to study the pathological evolution of demyelinating diseases, such as multiple sclerosis (MS). However,…”
    Get full text
    Journal Article
  6. 6

    FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection by Wiggermann, V, Hernández-Torres, E, Traboulsee, A, Li, D K B, Rauscher, A

    Published in American journal of neuroradiology : AJNR (01-02-2016)
    “…FLAIR and double inversion recovery are important MR imaging scans for MS. The suppression of signal from CSF in FLAIR and the additional suppression of WM…”
    Get full text
    Journal Article
  7. 7

    A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS by FREEDMAN, M. S, BAR-OR, A, FERENCZI, L, VERCO, T, OGER, J, TRABOULSEE, A, PATRY, D, YOUNG, C, OLSSON, T, LI, D, HARTUNG, H.-P, KRANTZ, M

    Published in Neurology (18-10-2011)
    “…To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA)…”
    Get full text
    Journal Article
  8. 8

    Multiple measures of corticospinal excitability are associated with clinical features of multiple sclerosis by Neva, J.L., Lakhani, B., Brown, K.E., Wadden, K.P., Mang, C.S., Ledwell, N.H.M., Borich, M.R., Vavasour, I.M., Laule, C., Traboulsee, A.L., MacKay, A.L., Boyd, L.A.

    Published in Behavioural brain research (15-01-2016)
    “…•Corticospinal excitability and inhibition are altered in individuals with MS.•Cortical and interhemispheric excitability accounts for unique variance in…”
    Get full text
    Journal Article
  9. 9

    Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial by Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Reder, A T, Goodin, D S, Bogumil, T, Beckmann, K, Wolf, C, Konieczny, A

    “…BackgroundEvidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16 y,…”
    Get full text
    Journal Article
  10. 10

    Acute disseminated encephalomyelitis following influenza vaccination by Shoamanesh, A, Traboulsee, A

    Published in Vaccine (26-10-2011)
    “…Highlights ► We present a case of post-vaccination acute disseminated encephalomyelitis (ADEM) following seasonal influenza vaccination. ► We perform a…”
    Get full text
    Journal Article
  11. 11

    Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents by Kang, H, Hii, M, Le, M, Tam, R, Riddehough, A, Traboulsee, A, Kolind, S, Freedman, M S, Li, D K B

    Published in American journal of neuroradiology : AJNR (01-09-2018)
    “…Dose-dependent association between hyperintensity in deep brain structures on unenhanced T1WIs and gadolinium-based contrast agent administrations has been…”
    Get full text
    Journal Article
  12. 12

    Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years by MacMillan, EL, Tam, R, Zhao, Y, Vavasour, IM, Li, DKB, Oger, J, Freedman, MS, Kolind, SH, Traboulsee, AL

    Published in Multiple sclerosis (01-01-2016)
    “…Background: Few biomarkers of progressive multiple sclerosis (MS) are sensitive to change within the two-year time frame of a clinical trial. Objective: To…”
    Get full text
    Journal Article
  13. 13

    Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS by Kappos, L, Traboulsee, A, Constantinescu, C, Erälinna, J-P, Forrestal, F, Jongen, P, Pollard, J, Sandberg-Wollheim, M, Sindic, C, Stubinski, B, Uitdehaag, B, Li, D

    Published in Neurology (26-09-2006)
    “…To conduct systematic long-term follow-up (LTFU) of patients in the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis by Laule, C., Vavasour, IM, Zhao, Y., Traboulsee, AL, Oger, J., Vavasour, JD, Mackay, AL, Li, DKB

    Published in Multiple sclerosis (01-06-2010)
    “…Background: Spinal cord involvement in multiple sclerosis (MS) is common and an important element in disability. Previous studies demonstrated smaller cervical…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS by Reder, A T, Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Goodin, D S, Bogumil, T, Beckmann, K, Konieczny, A

    Published in Neurology (08-06-2010)
    “…The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes…”
    Get full text
    Journal Article
  19. 19

    FLAIR2 improves LesionTOADS automatic segmentation of multiple sclerosis lesions in non-homogenized, multi-center, 2D clinical magnetic resonance images by Le, M., Tang, L.Y.W., Hernández-Torres, E., Jarrett, M., Brosch, T., Metz, L., Li, D.K.B., Traboulsee, A., Tam, R.C., Rauscher, A., Wiggermann, V.

    Published in NeuroImage clinical (01-01-2019)
    “…BACKGROUNDAccurate segmentation of MS lesions on MRI is difficult and, if performed manually, time consuming. Automatic segmentations rely strongly on the…”
    Get full text
    Journal Article
  20. 20

    Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial by Metz, LM, Li, D., Traboulsee, A., Myles, ML, Duquette, P., Godin, J., Constantin, M., Yong, VW

    Published in Multiple sclerosis (01-10-2009)
    “…Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate in relapsing—remitting multiple sclerosis. The effect of minocycline…”
    Get full text
    Journal Article